Effect of combined treatment with gonadotropin releasing hormone analogue and growth hormone in patients with central precocious puberty who had subnormal growth velocity and impaired height prognosis

G. Saggese; A. M. Pasquino; S. Bertelloni; G. I. Baroncelli; R. Battini; I. Pucarelli; M. Segni; G. Franchi

Effect of combined treatment with gonadotropin releasing hormone analogue and growth hormone in patients with central precocious puberty who had subnormal growth velocity and impaired height prognosis

G. Saggese, A. M. Pasquino, S. Bertelloni, G. I. Baroncelli, R. Battini, I. Pucarelli, M. Segni, G. Franchi

Fondazione Stella Maris

Research output: Contribution to journal › Article › peer-review

Abstract

Growth hormone-insulin-like growth factor-I status and response to growth hormone therapy (0.6 IU/kg/week sc, six times a week for 12 months) were evaluated in 12 girls (chronological age 9.4 ± 1.6 years) suffering from central precocious puberty with growth velocity less than 4 cm/year and no substantial increase or decrease in predicted adult height during gonadotropin releasing hormone (Gn-RH) analogue treatment (D-Trp⁶-LH-RH, 60 μg/kg im/28 days). At baseline, large variations were observed in nocturnal growth hormone (GH) means (pathological values (<3.6 μg/l) 33.3%), stimulated levodopa GH peaks (pathological values (

Original language	English
Pages (from-to)	299-304
Number of pages	6
Journal	Acta Paediatrica, International Journal of Paediatrics
Volume	84
Issue number	3
Publication status	Published - 1995

Keywords

Central precocious puberty
Gn-RH analogue treatment
Growth hormone
Growth velocity
Predicted adult height

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health

Cite this

Saggese, G., Pasquino, A. M., Bertelloni, S., Baroncelli, G. I., Battini, R., Pucarelli, I., Segni, M., & Franchi, G. (1995). Effect of combined treatment with gonadotropin releasing hormone analogue and growth hormone in patients with central precocious puberty who had subnormal growth velocity and impaired height prognosis. Acta Paediatrica, International Journal of Paediatrics, 84(3), 299-304.

Effect of combined treatment with gonadotropin releasing hormone analogue and growth hormone in patients with central precocious puberty who had subnormal growth velocity and impaired height prognosis. / Saggese, G.; Pasquino, A. M.; Bertelloni, S.; Baroncelli, G. I.; Battini, R.; Pucarelli, I.; Segni, M.; Franchi, G.

In: Acta Paediatrica, International Journal of Paediatrics, Vol. 84, No. 3, 1995, p. 299-304.

Research output: Contribution to journal › Article › peer-review

Saggese, G, Pasquino, AM, Bertelloni, S, Baroncelli, GI, Battini, R, Pucarelli, I, Segni, M & Franchi, G 1995, 'Effect of combined treatment with gonadotropin releasing hormone analogue and growth hormone in patients with central precocious puberty who had subnormal growth velocity and impaired height prognosis', Acta Paediatrica, International Journal of Paediatrics, vol. 84, no. 3, pp. 299-304.

Saggese, G. ; Pasquino, A. M. ; Bertelloni, S. ; Baroncelli, G. I. ; Battini, R. ; Pucarelli, I. ; Segni, M. ; Franchi, G. / Effect of combined treatment with gonadotropin releasing hormone analogue and growth hormone in patients with central precocious puberty who had subnormal growth velocity and impaired height prognosis. In: Acta Paediatrica, International Journal of Paediatrics. 1995 ; Vol. 84, No. 3. pp. 299-304.

@article{947f5410f9ca4f49b84da080f54549e0,

title = "Effect of combined treatment with gonadotropin releasing hormone analogue and growth hormone in patients with central precocious puberty who had subnormal growth velocity and impaired height prognosis",

abstract = "Growth hormone-insulin-like growth factor-I status and response to growth hormone therapy (0.6 IU/kg/week sc, six times a week for 12 months) were evaluated in 12 girls (chronological age 9.4 ± 1.6 years) suffering from central precocious puberty with growth velocity less than 4 cm/year and no substantial increase or decrease in predicted adult height during gonadotropin releasing hormone (Gn-RH) analogue treatment (D-Trp6-LH-RH, 60 μg/kg im/28 days). At baseline, large variations were observed in nocturnal growth hormone (GH) means (pathological values (<3.6 μg/l) 33.3%), stimulated levodopa GH peaks (pathological values (",

keywords = "Central precocious puberty, Gn-RH analogue treatment, Growth hormone, Growth velocity, Predicted adult height",

author = "G. Saggese and Pasquino, {A. M.} and S. Bertelloni and Baroncelli, {G. I.} and R. Battini and I. Pucarelli and M. Segni and G. Franchi",

year = "1995",

language = "English",

volume = "84",

pages = "299--304",

journal = "Acta Paediatrica, International Journal of Paediatrics",

issn = "0803-5253",

publisher = "Wiley-Blackwell",

number = "3",

}

TY - JOUR

T1 - Effect of combined treatment with gonadotropin releasing hormone analogue and growth hormone in patients with central precocious puberty who had subnormal growth velocity and impaired height prognosis

AU - Saggese, G.

AU - Pasquino, A. M.

AU - Bertelloni, S.

AU - Baroncelli, G. I.

AU - Battini, R.

AU - Pucarelli, I.

AU - Segni, M.

AU - Franchi, G.

PY - 1995

Y1 - 1995

N2 - Growth hormone-insulin-like growth factor-I status and response to growth hormone therapy (0.6 IU/kg/week sc, six times a week for 12 months) were evaluated in 12 girls (chronological age 9.4 ± 1.6 years) suffering from central precocious puberty with growth velocity less than 4 cm/year and no substantial increase or decrease in predicted adult height during gonadotropin releasing hormone (Gn-RH) analogue treatment (D-Trp6-LH-RH, 60 μg/kg im/28 days). At baseline, large variations were observed in nocturnal growth hormone (GH) means (pathological values (<3.6 μg/l) 33.3%), stimulated levodopa GH peaks (pathological values (

AB - Growth hormone-insulin-like growth factor-I status and response to growth hormone therapy (0.6 IU/kg/week sc, six times a week for 12 months) were evaluated in 12 girls (chronological age 9.4 ± 1.6 years) suffering from central precocious puberty with growth velocity less than 4 cm/year and no substantial increase or decrease in predicted adult height during gonadotropin releasing hormone (Gn-RH) analogue treatment (D-Trp6-LH-RH, 60 μg/kg im/28 days). At baseline, large variations were observed in nocturnal growth hormone (GH) means (pathological values (<3.6 μg/l) 33.3%), stimulated levodopa GH peaks (pathological values (

KW - Central precocious puberty

KW - Gn-RH analogue treatment

KW - Growth hormone

KW - Growth velocity

KW - Predicted adult height

UR - http://www.scopus.com/inward/record.url?scp=0028954958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028954958&partnerID=8YFLogxK

M3 - Article

C2 - 7780252

AN - SCOPUS:0028954958

VL - 84

SP - 299

EP - 304

JO - Acta Paediatrica, International Journal of Paediatrics

JF - Acta Paediatrica, International Journal of Paediatrics

SN - 0803-5253

IS - 3

ER -

Effect of combined treatment with gonadotropin releasing hormone analogue and growth hormone in patients with central precocious puberty who had subnormal growth velocity and impaired height prognosis

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this